Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors

Pediatric Blood and Cancer

Volumn 52, Issue 2, 2009, Pages 209-214

  Piqueras, Marta ^a   Navarro, Samuel ^a   Castel, Victoria ^b   Cañete, Adela ^b   Llombart Bosch, Antonio ^a   Noguera, Rosa ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

FISH; MYCN gene; Neuroblastic tumors; Tissue microarrays

Indexed keywords

ARTICLE; CHILD; CHROMOSOME DELETION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYCN GENE; NEUROBLASTOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; SCHOOL CHILD; TISSUE MICROARRAY; AGE; CELL DIFFERENTIATION; GENETICS; MUTATION; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG;

AGE FACTORS; CELL DIFFERENTIATION; CHILD; FEMALE; GENETIC MARKERS; HUMANS; MALE; MUTATION; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 59449084270     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21833     Document Type: Article

References (38)

1. van Noesel MM, Versteeg R. Pediatric neuroblastomas: Genetic and epigenetic "danse macabre." Gene 2004;325:1-15.
2. Altungoz O, Aygun N, Tumer S, et al. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma. Cancer Genet Cytogenet 2007;172:113-119.
3. Castel V, Grau E, Noguera R, et al. Molecular biology of neuroblastoma. Clin Transl Oncol 2007;9:478-483.
4. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216.
5. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005;17:7-13.
6. Spitz R, Betts DR, Simon T, et al. Favorable outcome of triploid neuroblastomas: A contribution to the special oncogenesis of neuroblastoma. Cancer Genet Cytogenet 2006;167:51-56.
7. Tonini GP, Pistoia V. Molecularly guided therapy of neuroblastoma: A review of different approaches. Curr Pharm Des 2006;12:2303-2317.
8. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-1124.
9. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007;369:2106-2120.
10. Okawa ER, Gotoh T, Manne J, et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 2008;27:803-810.
11. Fransson S, Martinsson T, Ejeskar K. Neuroblastoma tumors with favorable and unfavorable outcomes: Significant differences in mRNA expression of genes mapped at 1p36.2. Genes Chromosomes Cancer 2007;46:45-52.
12. Bown N, Lastowska M, Cotterill S, et al. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol 2001;36:14-19.
13. Brinkschmidt C, Christiansen H, Terpe HJ, et al. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol 2001;36:11-13.
14. Spitz R, Hero B, Ernestus K, et al. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin Cancer Res 2003;9:4835-4840.
15. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
16. Brown LA, Huntsman D. Fluorescent in situ hybridization on tissue microarrays: Challenges and solutions. J Mol Histol 2007;38:151-157.
17. Hassan S, Ferrario C, Mamo A, et al. Tissue microarrays: Emerging standard for biomarker validation. Curr Opin Biotechnol 2008;19:19-25.
18. Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007;39:655-660.
19. Makretsov NA, Huntsman DG, Nielsen TO, et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004;10:6143-6151.
20. Ambros IM, Benard J, Boavida M, et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 2003;21:2077-2084.
21. Subramaniam MM, Noguera R, Piqueras M, et al. p16INK4A (CDKN2A) gene deletion is a frequent genetic event in synovial sarcomas. Am J Clin Pathol 2006;126:866-874.
22. Subramaniam MM, Noguera R, Piqueras M, et al. Evaluation of genetic stability of the SYT gene rearrangement by break-apart FISH in primary and xenotransplanted synovial sarcomas. Cancer Genet Cytogenet 2007;172:23-28.
23. Scaruffi P, Parodi S, Mazzocco K, et al. Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization. Mol Diagn 2004;8:93-100.
24. Hoebeeck J, Speleman F, Vandesompele J. Real-time quantitative PCR as an alternative to Southern blot or fluorescence in situ hybridization for detection of gene copy number changes. Methods Mol Biol 2007;353:205-226.
25. Anderson J, Gibson S, Williamson D, et al. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR. Pediatr Blood Cancer 2006;46:820-824.
26. Spitz R, Oberthuer A, Zapatka M, et al. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 2006;45:1130-1142.
27. Layfield LJ, Willmore-Payne C, Shimada H, et al. Assessment of NMYC amplification: A comparison of FISH, quantitative PCR monoplexing and traditional blotting methods used with formalin-fixed, paraffin-embedded neuroblastomas. Anal Quant Cytol Histol 2005;27:5-14.
28. Zhang D, Salto-Tellez M, Do E, et al. Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 2003;34:362-368.
29. Egervari K, Szollosi Z, Nemes Z. Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract 2007;203:169-177.
30. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.[see comment]. N Engl J Med 1996;334:225-230.
31. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma [see comment]. N Engl J Med 2005;353:2243-2253.
32. Andersson AC, Stromberg S, Backvall H, et al. Analysis of protein expression in cell microarrays: A tool for antibody-based proteomics. J Histochem Cytochem 2006;54:1413-1423.
33. Giltnane JM, Rimm DL. Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 2004;1:104-111.
34. Lastowska M, Viprey V, Santibanez-Koref M, et al. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 2007;26:7432-7444.
35. Tajiri T, Tanaka S, Higashi M, et al. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors. J Pediatr Surg 2006;41:560-566.
36. Maris JM, Hii G, Gelfand CA, et al. Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform. Genome Res 2005;15:1168-1176.
37. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
38. Villamon E, Piqueras M, Mackintosh C, et al. Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma. Virchows Arch 2008;453:47-55.